BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Thursday that two abstracts highlighting research on its lead drug candidate ...
From organic street discs to sintered-iron race units, we break down every SPEC Clutch Stage to help you choose the right one ...
New disease-modifying agents are being evaluated in the clinic that could change the course of treatment for Alzheimer’s disease patients. Regulated industries like pharmaceuticals, biotech, and ...
MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory ...
18hon MSNOpinion
Rethinking climate change: Natural variability, solar forcing, model uncertainties, and policy implications
Current global climate models (GCMs) support with high confidence the view that rising greenhouse gases and other ...
A new CRISPR-powered light sensor can detect the faintest whispers of cancer in a single drop of blood.
Backed by more than 30 peer-reviewed human clinical studies supporting endogenous antioxidant activity, cellular ...
New peptide research blend shows promise as a game-changer in the fitness space BURTON, MI, UNITED STATES, January 19, ...
In Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3 trials. Early results suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a ...
Hoth Therapeutics, Inc. , a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced that the United States Patent and Trademark Office (USPTO) has ...
Ms. Warren added, “I am honored to serve Cue Biopharma in this capacity, and I look forward to continuing to support the Company’s corporate priorities and to be a part of this dedicated team.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results